Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFκB pathway.
Sign Up to like & getrecommendations! Published in 2019 at "Life sciences"
DOI: 10.1016/j.lfs.2019.116824
Abstract: AIMS Leflunomide is a disease modifying anti-rheumatic drug (DMARD) beneficial in refractory cases of rheumatoid arthritis. Since leflunomide approval, hepatotoxicity and instructions of liver function monitoring have been recommended. The current work aimed to explore… read more here.
Keywords: tlr4; pi3k mtor; leflunomide induced; mice ... See more keywords
Leflunomide‐induced liver injury: Differences in characteristics and outcomes in Indian and US registries
Sign Up to like & getrecommendations! Published in 2022 at "Liver International"
DOI: 10.1111/liv.15189
Abstract: Leflunomide, a disease‐modifying anti‐rheumatic drug, has been associated with elevations of serum aminotransferases. Herein, we describe the clinical, laboratory features and outcomes of 17 patients with leflunomide/teriflunomide hepatotoxicity from two large drug‐induced liver injury (DILI)… read more here.
Keywords: injury differences; differences characteristics; liver injury; induced liver ... See more keywords
Leflunomide-Induced Immune-Mediated Necrotizing Myopathy in a Patient With Rheumatoid Arthritis: A Case Report
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096221150636
Abstract: Immune-mediated necrotizing myopathy (IMNM) is a subtype of inflammatory myopathy that is characterized by proximal muscle weakness, markedly elevated serum creatine kinase, myopathic electromyographic findings, and muscle biopsies revealing necrosis or regeneration with sparse inflammatory… read more here.
Keywords: necrotizing myopathy; leflunomide; immune mediated; mediated necrotizing ... See more keywords